TY - JOUR A1 - Guerler, A. A1 - Moll, Sebastian A1 - Weber, Marcus A1 - Meyer, Holger A1 - Cordes, Frank T1 - Selection and flexible optimization of binding modes from conformation ensembles JF - Biosystems Y1 - 2008 UR - http://www.sciencedirect.com/science/article/pii/S0303264707001670 U6 - https://doi.org/DOI: 10.1016/j.biosystems.2007.11.004 VL - 92 IS - 1 SP - 42 EP - 48 ER - TY - JOUR A1 - Gürler, A. A1 - Moll, Sebastian A1 - Weber, Marcus A1 - Meyer, Holger A1 - Cordes, Frank T1 - Selection and flexible optimization of binding modes from conformation ensembles JF - Biosystems Y1 - 2007 ER - TY - JOUR A1 - Förster, C. A1 - Brauer, Arnd B. E. A1 - Fürste, J. A1 - Betzel, C. A1 - Weber, Marcus A1 - Cordes, Frank A1 - Erdmann, V. T1 - Visualization of the tRNA(Ser) acceptor step binding site in the seryl-tRNA synthetase JF - BBRC Y1 - 2007 VL - 362 IS - 2 SP - 415 EP - 418 ER - TY - GEN A1 - Cordes, Frank A1 - Weber, Marcus A1 - Schmidt-Ehrenberg, Johannes T1 - Metastable Conformations via successive Perron-Cluster Cluster Analysis of dihedrals N2 - Decomposition of the high dimensional conformational space of bio-molecules into metastable subsets is used for data reduction of long molecular trajectories in order to facilitate chemical analysis and to improve convergence of simulations within these subsets. The metastability is identified by the Perron-cluster cluster analysis of a Markov process that generates the thermodynamic distribution. A necessary prerequisite of this analysis is the discretization of the conformational space. A combinatorial approach via discretization of each degree of freedom will end in the so called ''curse of dimension''. In the following paper we analyze Hybrid Monte Carlo simulations of small, drug-like biomolecules and focus on the dihedral degrees of freedom as indicators of conformational changes. To avoid the ''curse of dimension'', the projection of the underlying Markov operator on each dihedral is analyzed according to its metastability. In each decomposition step of a recursive procedure, those significant dihedrals, which indicate high metastability, are used for further decomposition. The procedure is introduced as part of a hierarchical protocol of simulations at different temperatures. The convergence of simulations within metastable subsets is used as an ''a posteriori'' criterion for a successful identification of metastability. All results are presented with the visualization program AmiraMol. T3 - ZIB-Report - 02-40 KW - metastability KW - Perron-Cluster Cluster Analysis KW - curse of dimension KW - Hybrid Monte Carlo KW - significant dihedrals Y1 - 2002 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:0297-zib-7074 ER - TY - GEN A1 - Meyer, Holger A1 - Moll, Sebastian A1 - Cordes, Frank A1 - Weber, Marcus T1 - ConFlow? A new space-based Application for complete Conformational Analysis of Molecules N2 - Biochemical interactions are determined by the 3D-structure of the involved components - thus the identification of conformations is a key for many applications in rational drug design. {\sf ConFlow} is a new multilevel approach to conformational analysis with main focus on completeness in investigation of conformational space. In contrast to known conformational analysis, the starting point for design is a space-based description of conformational areas. A tight integration of sampling and analysis leads to an identification of conformational areas simultaneously during sampling. An incremental decomposition of high-dimensional conformational space is used to guide the analysis. A new concept for the description of conformations and their path connected components based on convex hulls and {\em Hypercubes}is developed. The first results of the {\sf ConFlow} application constitute a 'proof of concept' and are further more highly encouraging. In comparison to conventional industrial applications, {\sf ConFlow} achieves higher accuracy and a specified degree of completeness with comparable effort. T3 - ZIB-Report - 06-31 KW - conformational-analysis in-silico-screening drug-design Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:0297-zib-9258 ER -